WO1999028508A1 - Method of generating conditionally expressed mutant cells using expressible antisense sequences - Google Patents
Method of generating conditionally expressed mutant cells using expressible antisense sequences Download PDFInfo
- Publication number
- WO1999028508A1 WO1999028508A1 PCT/US1998/025808 US9825808W WO9928508A1 WO 1999028508 A1 WO1999028508 A1 WO 1999028508A1 US 9825808 W US9825808 W US 9825808W WO 9928508 A1 WO9928508 A1 WO 9928508A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- streptococcus
- gene
- inducible
- antisense
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 96
- 230000000692 anti-sense effect Effects 0.000 title claims description 72
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 146
- 230000012010 growth Effects 0.000 claims abstract description 12
- 230000014509 gene expression Effects 0.000 claims description 86
- 230000001939 inductive effect Effects 0.000 claims description 73
- 102000040430 polynucleotide Human genes 0.000 claims description 59
- 108091033319 polynucleotide Proteins 0.000 claims description 59
- 239000002157 polynucleotide Substances 0.000 claims description 58
- 239000013598 vector Substances 0.000 claims description 33
- 239000000411 inducer Substances 0.000 claims description 27
- 239000004098 Tetracycline Substances 0.000 claims description 25
- 229960002180 tetracycline Drugs 0.000 claims description 25
- 229930101283 tetracycline Natural products 0.000 claims description 25
- 235000019364 tetracycline Nutrition 0.000 claims description 25
- 150000003522 tetracyclines Chemical class 0.000 claims description 25
- 150000001875 compounds Chemical group 0.000 claims description 19
- 241000894006 Bacteria Species 0.000 claims description 17
- 230000004060 metabolic process Effects 0.000 claims description 14
- 230000004075 alteration Effects 0.000 claims description 12
- 230000001131 transforming effect Effects 0.000 claims description 11
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 10
- 241000588807 Bordetella Species 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 8
- 230000005670 electromagnetic radiation Effects 0.000 claims description 8
- 241000589968 Borrelia Species 0.000 claims description 6
- 241000589562 Brucella Species 0.000 claims description 6
- 241000606161 Chlamydia Species 0.000 claims description 6
- 108091026890 Coding region Proteins 0.000 claims description 6
- 241000186216 Corynebacterium Species 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 208000016604 Lyme disease Diseases 0.000 claims description 6
- 241000235070 Saccharomyces Species 0.000 claims description 6
- 241000607768 Shigella Species 0.000 claims description 6
- 241000194017 Streptococcus Species 0.000 claims description 6
- 241000191967 Staphylococcus aureus Species 0.000 claims description 5
- 229960003276 erythromycin Drugs 0.000 claims description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 4
- 229940023064 escherichia coli Drugs 0.000 claims description 4
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 3
- 241000589291 Acinetobacter Species 0.000 claims description 3
- 241000606750 Actinobacillus Species 0.000 claims description 3
- 241000186361 Actinobacteria <class> Species 0.000 claims description 3
- 241000607534 Aeromonas Species 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 241000193738 Bacillus anthracis Species 0.000 claims description 3
- 241000193755 Bacillus cereus Species 0.000 claims description 3
- 241000588779 Bordetella bronchiseptica Species 0.000 claims description 3
- 241000589876 Campylobacter Species 0.000 claims description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 3
- 241000222122 Candida albicans Species 0.000 claims description 3
- 241000588919 Citrobacter freundii Species 0.000 claims description 3
- 241000193403 Clostridium Species 0.000 claims description 3
- 241000193155 Clostridium botulinum Species 0.000 claims description 3
- 241000193468 Clostridium perfringens Species 0.000 claims description 3
- 241000193449 Clostridium tetani Species 0.000 claims description 3
- 241000588914 Enterobacter Species 0.000 claims description 3
- 241000520130 Enterococcus durans Species 0.000 claims description 3
- 241000194032 Enterococcus faecalis Species 0.000 claims description 3
- 241000194031 Enterococcus faecium Species 0.000 claims description 3
- 241000588698 Erwinia Species 0.000 claims description 3
- 241000186811 Erysipelothrix Species 0.000 claims description 3
- 241000588722 Escherichia Species 0.000 claims description 3
- 241000206602 Eukaryota Species 0.000 claims description 3
- 241000207201 Gardnerella vaginalis Species 0.000 claims description 3
- 241000606790 Haemophilus Species 0.000 claims description 3
- 241001501603 Haemophilus aegyptius Species 0.000 claims description 3
- 241000606768 Haemophilus influenzae Species 0.000 claims description 3
- 241000606766 Haemophilus parainfluenzae Species 0.000 claims description 3
- 241000589248 Legionella Species 0.000 claims description 3
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 3
- 241000589902 Leptospira Species 0.000 claims description 3
- 241000186781 Listeria Species 0.000 claims description 3
- 241000186779 Listeria monocytogenes Species 0.000 claims description 3
- 241000588621 Moraxella Species 0.000 claims description 3
- 241000186359 Mycobacterium Species 0.000 claims description 3
- 241000186366 Mycobacterium bovis Species 0.000 claims description 3
- 241000186362 Mycobacterium leprae Species 0.000 claims description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 3
- 241000187917 Mycobacterium ulcerans Species 0.000 claims description 3
- 241000204031 Mycoplasma Species 0.000 claims description 3
- 241000588653 Neisseria Species 0.000 claims description 3
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 3
- 241000588650 Neisseria meningitidis Species 0.000 claims description 3
- 241000187654 Nocardia Species 0.000 claims description 3
- 241000588769 Proteus <enterobacteria> Species 0.000 claims description 3
- 241000588770 Proteus mirabilis Species 0.000 claims description 3
- 241000588767 Proteus vulgaris Species 0.000 claims description 3
- 241000589516 Pseudomonas Species 0.000 claims description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 3
- 241000606701 Rickettsia Species 0.000 claims description 3
- 241000606695 Rickettsia rickettsii Species 0.000 claims description 3
- 241000607142 Salmonella Species 0.000 claims description 3
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims description 3
- 241000607720 Serratia Species 0.000 claims description 3
- 241000607717 Serratia liquefaciens Species 0.000 claims description 3
- 241000607764 Shigella dysenteriae Species 0.000 claims description 3
- 241000607762 Shigella flexneri Species 0.000 claims description 3
- 241000605008 Spirillum Species 0.000 claims description 3
- 241000191940 Staphylococcus Species 0.000 claims description 3
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 3
- 241001478878 Streptobacillus Species 0.000 claims description 3
- 241000193985 Streptococcus agalactiae Species 0.000 claims description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 3
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 3
- 241001505901 Streptococcus sp. 'group A' Species 0.000 claims description 3
- 241000193990 Streptococcus sp. 'group B' Species 0.000 claims description 3
- 241001468181 Streptococcus sp. 'group C' Species 0.000 claims description 3
- 241000194005 Streptococcus sp. 'group G' Species 0.000 claims description 3
- 241001655322 Streptomycetales Species 0.000 claims description 3
- 241000589886 Treponema Species 0.000 claims description 3
- 241000589884 Treponema pallidum Species 0.000 claims description 3
- 241000607598 Vibrio Species 0.000 claims description 3
- 241000607626 Vibrio cholerae Species 0.000 claims description 3
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 3
- 241000607479 Yersinia pestis Species 0.000 claims description 3
- 241000606834 [Haemophilus] ducreyi Species 0.000 claims description 3
- 241000617156 archaeon Species 0.000 claims description 3
- 229940065181 bacillus anthracis Drugs 0.000 claims description 3
- 229940095731 candida albicans Drugs 0.000 claims description 3
- 230000010261 cell growth Effects 0.000 claims description 3
- 229960003722 doxycycline Drugs 0.000 claims description 3
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 3
- 230000002147 killing effect Effects 0.000 claims description 3
- 229940007042 proteus vulgaris Drugs 0.000 claims description 3
- 229940075118 rickettsia rickettsii Drugs 0.000 claims description 3
- 229940007046 shigella dysenteriae Drugs 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 3
- 241000588748 Klebsiella Species 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims 1
- 244000052769 pathogen Species 0.000 abstract description 29
- 238000000338 in vitro Methods 0.000 abstract description 24
- 238000001727 in vivo Methods 0.000 abstract description 24
- 208000015181 infectious disease Diseases 0.000 abstract description 22
- 230000001717 pathogenic effect Effects 0.000 abstract description 20
- 230000009467 reduction Effects 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 239000013604 expression vector Substances 0.000 abstract description 2
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 70
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 37
- 239000013612 plasmid Substances 0.000 description 35
- 239000012634 fragment Substances 0.000 description 34
- 108020004414 DNA Proteins 0.000 description 33
- 230000000694 effects Effects 0.000 description 32
- 230000006698 induction Effects 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 24
- 239000000047 product Substances 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 22
- 230000001105 regulatory effect Effects 0.000 description 22
- 108700039887 Essential Genes Proteins 0.000 description 20
- 108020005544 Antisense RNA Proteins 0.000 description 19
- 239000003184 complementary RNA Substances 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 101710092462 Alpha-hemolysin Proteins 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 13
- 241000282326 Felis catus Species 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 13
- 239000013605 shuttle vector Substances 0.000 description 13
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 12
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 230000001018 virulence Effects 0.000 description 10
- 238000013459 approach Methods 0.000 description 9
- 230000002759 chromosomal effect Effects 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 231100000518 lethal Toxicity 0.000 description 8
- 230000001665 lethal effect Effects 0.000 description 8
- 101150055766 cat gene Proteins 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000004599 antimicrobial Substances 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000002703 mutagenesis Methods 0.000 description 6
- 231100000350 mutagenesis Toxicity 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 235000014469 Bacillus subtilis Nutrition 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 206010037596 Pyelonephritis Diseases 0.000 description 5
- 108020004682 Single-Stranded DNA Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 101710197219 Alpha-toxin Proteins 0.000 description 4
- 108050001049 Extracellular proteins Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 101710124951 Phospholipase C Proteins 0.000 description 4
- 238000010240 RT-PCR analysis Methods 0.000 description 4
- 241000823609 Staphylococcus aureus subsp. aureus RN4220 Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 238000001976 enzyme digestion Methods 0.000 description 4
- 208000013210 hematogenous Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 239000001974 tryptic soy broth Substances 0.000 description 4
- 235000019750 Crude protein Nutrition 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241000295644 Staphylococcaceae Species 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000002776 alpha toxin Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004784 molecular pathogenesis Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 101150024821 tetO gene Proteins 0.000 description 3
- 101150061166 tetR gene Proteins 0.000 description 3
- 102100026105 3-ketoacyl-CoA thiolase, mitochondrial Human genes 0.000 description 2
- 230000005730 ADP ribosylation Effects 0.000 description 2
- 108010003902 Acetyl-CoA C-acyltransferase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000006251 gamma-carboxylation Effects 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- -1 preferably streptococci Species 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000033458 reproduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 101150098072 20 gene Proteins 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108700003860 Bacterial Genes Proteins 0.000 description 1
- 108020004513 Bacterial RNA Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000037041 Community-Acquired Infections Diseases 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010023424 Kidney infection Diseases 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 108090000988 Lysostaphin Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000030538 Thecla Species 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012913 prioritisation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
Definitions
- the present invention provides a method for preparing conditionally expressed gene mutants, including conditional lethal mutants, and a method using such mutants to assess gene essentiality, and compositions useful in such methods.
- gene targets most sensitive to inhibition can be selected for the development of new therapies against selected pathogens.
- BACKGROUND OF THE INVENTION Identification, sequencing and characterization of genes is a major goal of modern scientific research. By identifying genes, determining their sequences and characterizing their biological function, it is possible to employ recombinant technology to produce large quantities of valuable gene products, e.g. proteins and peptides. Additionally, knowledge of gene sequences can provide a key to diagnosis, prognosis and treatment of a variety of disease states in plants and animals which are due to microbial pathogens and pathogenesis.
- Transposon mutants have also been tested in live animal models of infection (Miller, et al., Infect. Immun., 1989, 57:2758; and Bolker, et al, Mol. Gen. Genet., 1994, 245:547-552).
- comprehensive screening of bacterial genes is not possible due to the inability to identify mutants with attenuated virulence within pools of mutagenized bacteria and thus the huge number of mutants would require individual screening and large numbers of animals.
- Hensel, et al have developed an insertional mutagenesis system that uses transposons carrying unique DNA sequence tags for the isolation of bacterial virulence genes (Science, 1995, 269:400-403).
- each transposon mutant is tagged with a different DNA sequence.
- STM signature-tagged mutagenesis
- mutants in in vitro essential genes are lost in this system. This permits identification of bacteria recovered from hosts infected with a mixed population of mutants, as well as the negative selection of mutants with attenuated virulence. This method was used to identify virulence genes of Salmonella typhimurium in a murine model of typhoid fever. Further, Slauch, et al.
- IVET a method referred to as IVET which provides a means for identifying transcripts which are essentially absent in vitro, but are on throughout, or during, various phases of infection.
- these methods only provide information on the effect of the total absence or the specific up-regulation in vivo of the gene product in the organism and no information on gene essentiality.
- Conditional lethal mutants may also be created to abolish gene expression and identify essential genes (de Lorenzo, V, et al., Gene 123: 17-24 (1993); Neuwald, A. F., et al., Gene 125: 69-73(1993); and Takiff, H. E. , et al., J. Bacteriol.
- Ribozymes provide another way to lower gene expression levels by damaging a target gene or transcript.
- designing ribozymes to knock out the expression of specific genes may involve significant research and development.
- Antisense technology has been shown to be an effective means of down-regulating expression of specific genes. It has been widely used to interfere with eukaryotic gene expression through injection of synthetic oligonucleotides complementary to mRNA (Agrawal et al, Proc. Natl. Acad. Sci. USA, 1997, 94:2620-2625; and Zamecnik et al., Proc. Natl. Acad. Sci.
- the identification of virulent and essential genes for bacterial survival in vivo is a powerful approach for studying molecular pathogenesis and determining molecular targets for antibiotic discovery.
- the combination of an antisense strategy with a regulatory expression system may offer a useful method of studying the molecular pathogenesis of bacterial pathogens.
- An aspect of the invention herein was to define novel virulence factors by inducing antisense RNA to decrease the expression of known genes during different stages of infection and to target essential genes in vitro and in vivo. Indeed, the Tn70- encoded tet repressor has been successfully used to regulate expression of specific genes not only in Bacillus subtilis (Geissendorfer et al, Appl.
- xylltet chimeric promoter Geissendorfer et al., Appl. Microbiol. BiotechnoL, 1990, 33:657-663.
- This promoter system employs elements of both the xylose and tetracycline systems and has been shown to be strongly inducible in B. subtilis using sub-inhibitory concentrations of tetracycline.
- a tet regulatory system in Staphylococcus aureus was constructed and cloned an antisense hla fragment downstream of the inducible xyl/tet promoter-operator fusion to investigate whether this tet regulatory system can function in S. aureus in vitro and in vivo and whether inducible antisense hla downregulates expression of the chromosomal hla gene.
- the present invention provides methods for creating libraries of conditionally expressed and conditional lethal mutant bacteria and other cells using an antisense strategy (for a description of antisense polynucleotides used in bacteria, see Kerndole, et al, Infection and Immunity 65(1): 179 (1997)). Methods are also provided which allow for the determination of whether a particular gene is essential to the growth or life of the organism being tested. Such genes are particularly useful as targets for screening for antimicrobial compounds.
- the invention provides a method for determining gene essentiality comprising the steps of: transforming a host cell or group of host cells with a vector comprising an inducible gene control region expressibly linked to a library of random DNA fragments; inducing the inducible gene control region with an inducer; and detecting an alteration in the metabolism of the host cell or group of host cells due to antisense expression.
- a method is also provided for determining gene essentiality comprising the steps of: transforming a host cell or group of host cells with a vector comprising an inducible gene control region expressibly linked to an antisense polynucleotide sequence; inducing the inducible gene control region with an inducer; and detecting an alteration in the metabolism of the host cell or group of host cells.
- a method for determining gene essentiality comprising the steps of: transforming a host cell or group of host cells with a vector comprising an inducible gene control region expressibly linked to random antisense polynucleotide sequences; inducing the inducible gene control region with an inducer; and detecting killing or slowed growth of the host cell or group of host cells.
- a method for determining gene essentiality comprising the steps of: transforming a host cell or group of host cells with a vector comprising an inducible gene control region expressibly linked to a library of random DNA fragments ; inducing the inducible gene control region with an inducer; detecting an alteration in the metabolism of the host cell or group of host cells; and isolating the full length gene that comprises the coding sequence of the selected polynucleotide sequence or comprises the coding sequence of the complementary sequence of the selected polynucleotide sequence.
- the methods of the invention may comprise a host cell as defined elsewhere herein.
- the methods may comprise an inducible promoter or an operator and inducible repressor.
- the methods may also comprise a selected polynucleotide sequence that is an antisense sequence.
- Selected polynucleotide sequences in the methods may be selected from an organism.
- Preferred inducers of the invention comprise a chemical compound or electromagnetic radiation.
- Such chemical compound inducers include, for example, IPTG, doxycycline, erythromycin, and tetracycline.
- Such electromagnetic radiation includes, for example, X-rays, gamma rays, beta rays, UV light, and visible light, red visible light and green visible light. Methods are also provided wherein the alteration in the metabolism is slowed cell growth, cell death, or cell stasis.
- Figure 1 shows a schematic of the tetracycline inducible shuttle vector pYJ90.
- tetR tetracycline resistant repressor-encoding gene
- PR the improved tetR promoter
- ⁇ xylltetO the xyl-tet promoter-operator fusion
- pUC19 ori and pE194 ori origins of replication from pUC19 and pE194, respectively, allowing plasmid replication in Gram-negative and Gram-positive host bacteria.
- Figure 2 shows dependence of CAT activity on tetracycline concentration.
- S . aureus YJ335 was incubated in TSB with 5ng/ml of Erm to early log phase and different doses of tetracycline were added to aliquotted cultures. Two milliliters of each culture were transferred into a new tube and the cells were harvested by centrifugation three hours after the addition of tetracycline. Crude protein preparations were used to anaylze CAT activity. Specific CAT activity is defined as units of CAT activity per milligram of total protein.
- Figure 3 shows kinetics of tetracycline induction in S. aureus. Strain YJ335 was incubated to early log phase in TBS and 250ng/ml of tetracycline was added to the culture.
- FIG. 4 shows construction of the tetracycline-inducible shuttle vector containing hla in the antisense and sense orientations.
- a 621-bp fragment of hla containing the promoter region was inserted into the EcoRW site of plasmid pYJ335.
- Two recombinants, pYJ318-7 and pYJ318-16, represent hla cloned in the antisense and sense hla orientations, respectively.
- Figure 5 shows Northern blot analysis of sense hla and antisense hla transcription.
- Digoxigenin-labeled single- stranded DNA oligonucleotide probes hybridized specifically with either induced sense hla RNA (YJ318-16 +Tc) or induced antisense hla RNA (YJ318-
- Figure 6 shows Western blot analysis of ⁇ -hemolysin expressed in strain WCUH29 and its isogenic strains with or without tetracycline induction.
- the molecular weight markers are biotinylated low molecular weight SDS-PAGE standards (Bio-Rad Lab., Hercules, CA).
- Figure 7 shows RT-PCR analysis of transcription of cat (A) and hla (B) following in vivo induction with tetracycline. Plasmid DNA was used as a positive control (pYJ335 and pYJ318- 16). Negative controls were samples prepared without RT or template DNA.
- Antisense polynucleotide means a polynucleotide sequence that is capable of hybridizing to or is complementary to, in whole or in part, another polynucleotide sequence.
- “Expressibly linked” means a first polynucleotide sequence joined to a second polynucleotide sequence, such as by ligation, so that they act together to express a gene product, such as a DNA, an RNA or a protein.
- “Host cell” is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous polynucleotide sequence and includes a cell or cells of a (i) prokaryote, including but not limited to, a member of the genus Streptococcus, Staphylococcus, Bordetella, Corynebacterium, Mycobacterium, Neisseria, Haemophilus, Actinomycetes, Streptomycetes, Nocardia, Enterobacter, Yersinia, Fancisella, Pasturella, Moraxella, Acinetobacter, Erysipelothrix, Branhamella, Actinobacillus, Streptobacillus, Listeria, Calymmatobacterium, Brucella, Bacillus, Clostridium, Treponema, Escherichia, Salmonella, Kleibsiella, Vibrio, Proteus, Erwinia, Borrelia,
- inducer means a composition of matter or electromagnetic radiation to which an inducible gene control region responds by altering the expression of an expressibly linked polynucleotide.
- inducers include those well known in the art, such as UV radiation and IPTG, as well as those disclosed herein.
- “Inducible gene control region” means a polynucleotide sequence that responds to a composition of matter or electromagnetic radiation and alters the expression of an expressibly linked polynucleotide. Examples of such regions include inducible promoters or derepressible operator/promoters combinations, many of which are well known.
- isolated means altered “by the hand of man” from its natural state, i.e., if it occurs in nature, it has been changed or removed from its original environment, or both.
- a polynucleotide or a polypeptide naturally present in a living organism is not
- isolated but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is “isolated”, as the term is employed herein.
- Polynucleotide(s) generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
- Polynucleotide(s) include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions or single-, double- and triple-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double- stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded, or triple-stranded regions, or a mixture of single- and double- stranded regions.
- polynucleotide refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA.
- the strands in such regions may be from the same molecule or from different molecules.
- the regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules.
- One of the molecules of a triple-helical region often is an oligonucleotide.
- the term "polynucleotide(s)” also includes DNAs or RNAs as described above that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotide(s)" as that term is intended herein.
- DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples are polynucleotides as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art.
- the term "polynucleotide(s)" as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including, for example, simple and complex cells. "Polynucleotide(s)” also embraces short polynucleotides often referred to as oligonucleotide(s).
- Polypeptide(s) refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds.
- Polypeptide(s) refers to both short chains, commonly referred to as peptides, oligopeptides and oligomers and to longer chains generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene encoded amino acids.
- Polypeptide(s) include those modified either by natural processes, such as processing and other post-translational modifications, but also by chemical modification techniques. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature, and they are well known to those of skill in the art.
- Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains, and the amino or carboxyl termini.
- Modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation, ADP-ribosylation, selenoylation
- Polypeptides may be branched or cyclic, with or without branching. Cyclic, branched and branched circular polypeptides may result from post-translational natural processes and may be made by entirely synthetic methods, as well.
- Selected polynucleotide sequence means an isolated polynucleotide sequence that is complementary, in whole or part, to a target sequence, or is an isolated polynucleotide randomly selected from a pathogen polynucleotide sequence library.
- Target means a polynucleotide, such as a gene, that is desired to be targeted to determine the effect of altering its expression level on the metabolism or reproduction of the cell comprising such target.
- Gene knockout studies provide information on the effect of the total absence of a gene product.
- antimicrobial therapies can rarely achieve the complete abolition of activity of a given gene product.
- gene knockouts cannot be created (by simple insertion/deletion mutagenesis, for example) if the gene products are essential to viability in vitro.
- the present invention was based, in part, on studies undertaken in order to develop a system whereby essential genes could be studied in vitro and in vivo in a pathogen, particularly a pathogenic bacterium or organism, such as 5. aureus.
- antisense fragments to down-regulate gene expression has several advantages over other methods.
- the use of antisense can be a powerful tool to aid in understanding a gene's function without necessarily completely eliminating its activity.
- antisense technology allows one to very easily manipulate the expression of a gene in order to observe the consequences of a lethal mutation over time.
- the ease with which such antisense fragments can be constructed can be directly contrasted with the tedium of constructing null mutations and promoter-down mutations.
- the antisense technology was combined with an inducible promoter system to selectively induce expression of an antisense hla fragment as an illustrative example of an embodiment of the invention.
- Tc 0.25nanograms/ml tetracycline
- ⁇ -hemolysin is a well-characterized secreted protein with ample, accessible tools with which to study it.
- ⁇ -toxin production can be screened on plates and its absence results in a defined effect, namely, attenuation of virulence in vivo.
- ⁇ -hemolysin expression down-regulated by antisense under the control of its own promoter had been previously demonstrated and thus would be a good comparison for certain embodiments of the invention.
- the inducible xyl/tet promoter used in this embodiment had been previously shown to be functional in B. subtilis (Geissendorfer et al, Appl. Microbiol. BiotechnoL, 1990, 33:657-663).
- This promoter incorporates elements of both the xylose- and tetracycline- inducible systems, resulting in a tightly-regulated, strong promoter that is induced with low concentrations of tetracycline.
- B. subtilis using 0.4 ⁇ g/ml of Tc, 100-fold induction was obtained within three hours. Results exemplified herein using this promoter construct in S. aureus compare with this earlier one: there was observed a 70-fold level of induction with 0.25ng/ml of Tc in the same time period, as shown by monitoring specific CAT activity over time.
- This inducible promoter system was then used to selectively induce expression on a gene, ⁇ -hemolysin, during in vivo infection.
- a murine model of hematogenous pyelonephritis was chosen to illustrate certain embodiments of the invention, as it results in a localized kidney infection from which bacteria are readily recovered. Results exemplified herein demonstrate that, using low levels of tetracycline given orally, one can effectively induce expression of ⁇ -hemolysin. This result will enable us to examine essential genes in this manner, using different concentrations of inducer to control the levels of antisense expressed, and thus down-regulate expression to different degrees.
- this promoter system makes it possible to observe the effects of different levels of down-regulation of an essential gene without completely inactivating it.
- This type of analysis can aid in the development of antimicrobial agents by decreasing levels of a target gene product and perhaps rendering cells more susceptible.
- this technology may be applied to a more random approach, i.e. the development of a conditional-lethal screen for essential genes, under both in vitro and in vivo conditions.
- the present invention provides a convenient, rapid and cost-effective method for the creation of mutants as a result of conditional gene down-regulation. Certain of these mutants are conditional lethal mutants.
- the present invention also provides a method for determining pathogen sensitivity to varying levels of reduction of a gene product and is applicable to genes essential in vitro since reduction in levels of the gene product only occurs under conditions of induction. The decrease in gene expression for a selected target can be monitored and correlated with the progression of the infection and/or viable counts recovered from infected tissue. Using this method, genes from a selected pathogen which are most sensitive to inhibition in vivo can be identified and selected as targets for the development of new intervention therapies.
- a conditional lethal method is also provided for identifying essential genes using antisense technology.
- Preferred methods are also provided for using an inducible promoter(s) to selectively express antisense library clones. Colonies that fail to grow under these conditions are likely to be carrying plasmids comprising insert DNA which, when expressed, produce an antisense RNA fragment that inhibits translation of an essential gene transcript. This strategy facilitates identification of such essential genes as they can be readily identified by sequencing the plasmid inserts. In addition, this strategy can be used to screen for both in vitro and in vivo essential genes.
- Preferred methods of the invention comprise inducible promoter(s), examples of which are set forth elsewhere herein.
- Preferred methods of the invention also comprise shuttle plasmids which can replicate in both Escherichia coli and Staphylococcus aureus.
- a library of DNA fragments may be cloned into the shuttle plasmids of the invention.
- An example of a library of DNA fragments useful in the methods and/or in the plasmids of the invention preferably comprise 600 to 1000 base pair fragments.
- the methods of the invention (i) allow for evaluation of partial gene repression, (ii) facilitate identification of essential genes as the cloned antisense fragment can be used as a probe for the full-length gene sequence, (iii) pools of mutants can be examined en masse in vivo, (iv) after infection, clones which are not recovered (identified by subtractive hybridization) are likely to contain antisense fragments corresponding to in vivo essential genes, (v) antisense effect can be measured directly, by determining levels of antisense expression and correlating with degree of in vivo attenuation, and (vi) can possibly also identify genes for which a partial down regulation is lethal by varying levels of inducer.
- pathogen it is meant any organism which is capable of infecting an animal or plant and replicating its nucleic acid sequences in the cells or tissue of the animal or plant. Such a pathogen is generally associated with a disease condition in the infected animal or plant. Such pathogens may include, but are not limited to, viruses, which replicate intra- or extra-cellularly, or other organisms such as bacteria, fungi or parasites, which generally infect tissues or the blood. Certain pathogens are known to exist in sequential and distinguishable stages of development, e.g., infection initiation, latent stages, infective stages, and stages which cause symptomatic diseases. In these different states, the pathogen is anticipated to rely upon different genes as essential for survival and pathogenesis. Preferred host cells of the invention are pathogens. The methods of the invention may comprise a host cell as described elsewhere herein.
- a method whereby total genomic DNA of a pathogen or host cell is isolated. Random fragments of the size 0.6 - 1 kb are expressibly linked to an inducible expression control sequence. This method will allow for the determination of whether the expression of a sequence, or gene comprising the sequence, is essential for the cell's growth or survival. This essentiality may be tested under various conditions as described herein. Optimization of the expression of the antisense RNA to inhibit target gene expression may be first carried out in vitro using a standard controllable promoter such as pSpac, TetR, etc., induced by IPTG and tetracycline, respectively.
- a standard controllable promoter such as pSpac, TetR, etc.
- controllable and inducible promoters known in the art, as well as others taught herein, may also be used for this purpose.
- Promoters specifically induced by the in vitro environment i.e., the acetyl-CoA-acyltransferase promoters, may also be used for this purpose.
- the expression vector may then be introduced into the selected pathogen using standard techniques.
- Introduction of the vector carrying the antisense polynucleotide sequence construct into the selected pathogen should not affect growth or expression of the target gene in vitro when the antisense expression construct is uninduced.
- This target will be a preferred target for antimicrobial compound screening.
- RNA expression can be monitored by RT-PCR of total mRNA isolated from infected tissue at various times during the infection and correlated with housekeeping gene controls and viable cell counts. Reduction in target mRNA is correlated with infection progression including disease pathology. Luminescence in thin tissue sections allows determination of the numbers of metabolically active pathogens and viable cell counts allow for the prioritization of gene targets for development of therapeutic agents.
- genes and gene products identified according to the method of the present invention may then be used in the design of therapeutic and diagnostic agents.
- genes identified in accordance with this method as essential to a selected pathogen in the infection process and proteins encoded thereby may serve as targets for the screening and development of natural or synthetic chemical compounds which have utility as therapeutic drugs for the treatment of infection by this pathogen.
- a compound capable of binding to such protein encoded by such gene and inhibiting its biological activity may be useful as a drug component preventing diseases or disorders resulting from the growth of a particular organism.
- compounds which inhibit expression or reduce expression of an essential gene are also believed to be useful therapeutically.
- a method for identifying compounds which specifically bind to or inhibit proteins encoded by these gene sequences can include simply the steps of contacting a selected protein or gene product with a test compound to permit binding of the test compound to the protein; and determining the amount of test compound, if any, which is bound to the protein. Such a method may involve the incubation of the test compound and the protein immobilized on a solid support. Still other conventional methods of drug screening can involve employing a suitable computer program to determine compounds having similar or complementary structure to that of the gene product or portions thereof and screening those compounds for competitive binding to the protein. Such compounds may be incorporated into an appropriate therapeutic formulation, alone or in combination with other active ingredients. Methods of formulating such therapeutic compositions, as well as suitable pharmaceutical carriers, and the like are well known to those of skill in the art.
- the present invention is believed to provide targets for screening compounds capable of interacting with these genes, or encoded proteins or fragments thereof, and either enhancing or decreasing the biological activity, as desired.
- Such compounds are also encompassed by this invention.
- the invention also provides a method for determining gene essentiality comprising the steps of: transforming a host cell or group of host cells with a vector comprising an inducible gene control region expressibly linked to a random polynucleotide sequence; inducing the inducible gene control region with an inducer; and detecting an alteration in the metabolism of the host cell or group of host cells.
- a method for determining gene essentiality comprising the steps of: transforming a host cell or a group of host cells with a vector comprising an inducible gene control region expressibly linked to a random antisense polynucleotide sequence; inducing the inducible gene control region with an inducer; and detecting an alteration in the metabolism of the host cell or group of host cells.
- the detection step may be carried out by observing alterations in metabolism in the form of killing or slowed growth of the host cell or group of host cells, as the case may be.
- Sequences whose lowered expression alters the metabolism of the cell are useful candidate targets for antimicrobial compound screening. In view of this, these sequences, and any full length gene coding sequence comprising such sequences, may be isolated using methods well known to the skilled artisan. These methods include, among others, PCR, cloning, sequencing.
- the structure of the vectors useful in the methods of the invention may take many forms.
- the vectors may comprise an inducible promoter or an operator and inducible repressor. Using these gene expression control regions one may regulate the level of expression of the antisense transcription unit.
- Further particularly preferred vector embodiments comprise two inducible gene control regions, each expressibly linked to each terminus of an inserted DNA fragment. Such insertional vectors allow for the insertion of two inducible gene control regions transcribing in opposite directions. These vectors having two promoters and an inserted element are also useful to obtain antisense expression regardless of the insert direction. Whole libraries may be screened using vectors comprising such dual inducible gene expression control regions in the methods of the invention.
- random fragments of genomic DNA from the selected pathogen are expressibly linked between the two inducible gene expression control regions.
- the inducible gene expression control regions are each induced by a different inducer.
- These expression constructs are then randomly ligated into a vector and the vector is introduced into a pool of pathogen host cells. These cells are replica plated on a first medium comprising an inducer for the first inducible gene control region, on a second medium comprising an inducer for the second inducible gene control region, and on a third medium lacking any inducer.
- Colonies which fail to grow on the first and/or second media but grow on the third medium contain an essential polynucleotide sequence (e.g., a gene or transcript) corresponding to the antisense polynucleotide sequence of the cloned polynucleotide sequence.
- an essential polynucleotide sequence e.g., a gene or transcript
- Vectors used in the methods of the invention include, for example, any polynucleotide that may be introduced into a pathogen cell, including polynucleotides stably introduced into the host cell's genome.
- preferred vectors of the invention include shuttle plasmids, which can replicate in both gram (-) and gram (+) hosts to facilitate cloning and library construction.
- Gene expression elements may be engineered into theses vectors in preferred embodiments
- particularly preferred embodiments comprise two inducible gene control regions It is preferred that one such region is expressibly linked to each terminus of the cloned polynucleotide sequence
- Vectors useful in the invention may comprise transc ⁇ ptional or translational terminators ligated upstream or downstream of the antisense polynucleotide in order to keep gene expression off until specific induction is desired
- Both eukaryotic and prokaryotic terminators are known in the art
- Vectors of the invention may contain random sequences or may be used to introduce a sequence that has been partially characterized, such as by RT-PCR data This targeted approach may be used to complement known methods for carrying out gene essentiality analyses, such as STM and RT-PCR This approach would allow the skilled artisan to examine a limited number of clones in vivo, thereby reducing the complexity of the library being
- Inducers of the inventions may be any compound or EMR that can induce gene expression driven by a polynucleotide sequence, preferably driven by a promoter
- Preferred inducers of the invention comprise a chemical compound or electromagnetic radiation
- host cells can be genetically engineered to incorporate expression systems or portions thereof or polynucleotides of the invention
- Introduction of a polynucleotide into the host cell can be effected by methods described in many standard laboratory manuals, such as Davis et al , BASIC METHODS IN MOLECULAR BIOLOGY, (1986) and Sambrook et al , MOLECULAR CLONING A LABORATORY MANUAL, 2nd Ed , Cold Spring Harbor Laboratory Press, Cold Sp ⁇ ng Harbor, N Y (1989), such as, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic pid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction and infection
- bactenal cells preferably streptococci, staphylococci, enterococci E coli, streptomyces and Bacillus subtilis cells
- fungal cells such as yeast cells and Asperg ⁇ lus cells
- insect cells such as Drosoph ⁇ a S2 and Spodoptera Sf9 cells
- animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 and Bowes melanoma cells
- pathogens such as bactenal cells, preferably streptococci, staphylococci, enterococci E coli, streptomyces and Bacillus subtilis cells
- fungal cells such as yeast cells and Asperg ⁇ lus cells
- insect cells such as Drosoph ⁇ a S2 and Spodoptera Sf9 cells
- animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 and Bowes melanoma cells
- Such vectors include, among others, chromosomal, episomal and virus-derived vectors, e.g., vectors derived from bacterial plasmids, from genetic elements, such as cosmids and phagemids.
- the expression system constructs may contain control regions that regulate as well as engender expression.
- any system or vector suitable to maintain, propagate or express polynucleotides and/or to express a polypeptide in a host may be used for expression in this regard.
- the appropriate DNA sequence may be inserted into the expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al, MOLECULAR CLONING, A LABORATORY MANUAL, (supra).
- pCUl Gram-negative to Gram-positive shuttle vector
- pWM401 Gram-negative to Gram-positive shuttle vector
- pHV33 Gram- negative to Gram-positive shuttle vector
- pHV1431 Gram-negative to Gram-positive shuttle vector
- pNZ12 Gram-negative to Gram-positive shuttle vector
- pMH109 contains multiple cloning sites Hudson et al., Gene, 1986, 48:93- upstream of the cat gene 100
- pWH353 contains the tet regulatory Geissendorfer et al., Appl. elements including the tetR gene Microbiol. BiotechnoL, 1990, and its promoter with a poly-A 33:657-663 block, and the xyl/tet promoter- operator fusion pYJ82 contains the cat gene cloned into Yanisch-Perron et al., Gene, 1985, the Ec ⁇ RI and BamHl sites of 33: 103-119 pUC19 pYJ90 contais the origin of replication Horinouchi et al., J.
- BacterioL from plasmids pE194 and pUC19, 1982, 150:804-814 which allows replication in Gram- positive and Gram-negative bacteria; contains Erm and Ap resistance markers and a multiple cloning site pYJ 101 contains the tet regulatory element Described herein inserted into the Cla ⁇ and Hind ⁇ ll sites of pBluescript II KS (Stratagene, La Jolla, CA) pYJ 103 contains the cat gene cloned into Described herein
- EcoRl and Pstl sites of pYJIOl pYJ335 contains the tet regulatory element Described herein and the cat gene cloned into the Sail site of pYJ90 pYJ318-7 contains a 621 -bp hla fragment in Described herein the antisense orientation cloned into the Smal site of pYJ335 pYJ318- 16 contains the hla fragment in the Described herein sense orientation cloned into the Smal site of pYJ335
- Inducible promoters useful in the methods of the invention may be any inducible promoter, for example, a doxycycline inducible promoter (see Kistner et al, PNAS USA 93: 10933 (1996)), erythromycin resistance promoter (see Ross et al, Gene 183: 143 (1996)), a macrolide resistance promoter (see Shuwsei et al, Antimicrobial Agents and Chemotherapy 41(3): 530 (1997), or a tetracycline resistance promoter (see Geissendorfer et al, Appl.
- a doxycycline inducible promoter see Kistner et al, PNAS USA 93: 10933 (1996)
- erythromycin resistance promoter see Ross et al, Gene 183: 143 (1996)
- a macrolide resistance promoter see Shuwsei et al, Antimicrobial Agents and Chemotherapy 41(3): 530 (1997), or a tetracycline resistance
- Termination sequences useful in the invention include, for example, rho-dependent termination signal, S. aureus and S. pneumoniae termination signals, rho-independent termination.
- the invention further relates to packs and kits comprising one or more containers, preferably rigid, filled with one or more of the ingredients of the aforementioned compositions, such as the vectors, of the invention.
- antisense RNA can be a useful tool for studying molecular pathogenesis.
- a tet regulatory expression system was constructed in a shuttle vector.
- this regulatory system showed a 70-fold level of induction in vitro and very strong dose dependence; it also functioned in vivo in a murine model of hematogenous pyelonephritis in combination with induction by oral administration of tetracycline.
- S. aureus RN4220 was derived from chemical mutagenesis of S.aureus 8325-4 and is able to accept heterologous DNA (R.P. Novick, Molecular Biology of the Staphylococci. VCH Publishers, New York, NY, 1990, 1-40).
- S. aureus WCUH29 is a virulent alpha-toxin producing clinical isolate.
- S. aureus strains were cultured in tryptic soy broth (TSB; BBL) or TSB-agar medium. To maintain selection of plasmid pYJ90, S. aureus was grown in culture medium containing erythromycin (Erm 5 ⁇ g/ml).
- Escherichia coli strains were grown in Luria-Bertani broth (LB) containing chloramphenicol (Cm 20 ⁇ g/ml), Erm (300 ⁇ g/ml), or ampicillin (Ap lOO ⁇ g/ml) as appropriate.
- LB Luria-Bertani broth
- plasmids pUC19 (Yanisch-Perron et al., Gene, 1985, 33:103-1 19) and pE194 (Horinouchi et al., J. BacterioL, 1982, 150:804- 814) were digested with Ndel, purified, ligated, and transformed into E.coli DH5- ⁇ by electroporation. Transformants were selected on LB-agar containing Ap (lOO ⁇ g/ml) and Erm (300 ⁇ g/ml). One recombinant, pYJ90, was confirmed by restriction enzyme digestion and electroporated into S.
- aureus RN4220 as previously described (Kraemer et al., Cur. Microbiol., 1990, 21 :373-376 and R.P. Novick, Molecular Biology of the Staphylococci. VCH Publishers, New York, NY, 1990, 1 -40). Transformants were selected on TSA containing Erm (5 ⁇ g/ml). The stability of plasmid pYJ90 in S. aureus was determined by passaging a culture six times in medium lacking antibiotics and analyzing plasmid DNA in the bacterial culture.
- the Clal - Hin ⁇ lll fragment containing the tetR gene (which encodes the tet repressor), its promoter (PR), and the strong xyl/tet promoter-operator fusion ⁇ P ⁇ yl/tet ⁇ ) was excised from plasmid pWH353, and cloned into plasmid pBluescript II KS (Stratagene. La Jolla, CA).
- the resulting plasmid, pYJIOl was digested with EcoRl and Pstl and ligated to the £c ⁇ RI - Pstl fragment of pYJ82 containing a promoterless cat gene followed by a transcriptional terminator.
- This new construct was named pYJ103 and the fragment containing the tetR/P /P ⁇ yl/tetO' cat re gi° n was cloned into pYJ90 via the Sail site.
- the resulting plasmid, PYJ335, was confirmed by restriction enzyme digestion and DNA sequencing, and then electroporated into S. aureus RN4220.
- One of transformants, YJSB335 was confirmed and used to make phage lysates using S. aureus phage ⁇ 1 1.
- a 621 bp hla fragment was generated by PCR amplification using primers hla ⁇ or64 (5' GGGGGGCCCGGGTATGTCTTTTCCTTGTTTCA 3')[SEQ ID NO: l] and W ⁇ Rev684 (5'GGGGGGCCCGGGATCAGGTAGTTGCAACTG 3') [SEQ ID NO:2] corresponding to nucleotides 64 - 83 and 684 - 701 , respectively.
- Boldface nucleotides correspond to the Smal restriction enzyme recognition site and underlined nucleotides correspond to the hla coding sequence (Gray et al., Infect. Immun., 1984, 46:615-618).
- the amplified hla fragment contains the hla promoter region.
- the PCR product was digested with Smal and ligated downstream of the xyl/tetO promoter-operator fusion of pYJ335.
- the resulting plasmids, pYJ318-7 and pYJ318- 16, which contain hla in the antisense and sense orientations, respectively, were separately electroporated into S. aureus.
- plasmids pYJ318-6 and pJY318-16 were introduced into this strain by phage transduction.
- Phage ⁇ l 1 was used to make phage lysates by infecting S.aureus YJSB335, YJSB318-7, and YJSB318-16 grown in top agar (TSB containing 0.7%agar and 5mMCaCl2).
- the phage lysates were sterilized by passing each through a 0.45 ⁇ m pore size filter and titered on S. aureus RN4220.
- Transductions were performed by incubating 5 x 10 ⁇ CFU of WCUH29 cells with lOO ⁇ l of phage lysate (10 9 -10 10 pfu) and 5mM CaCl 2 at 37° C for 30 minutes.
- lOO ⁇ l of phage lysate 10 9 -10 10 pfu
- 5mM CaCl 2 5mM CaCl 2 at 37° C for 30 minutes.
- One milliliter of ice-cold 20mM sodium citrate was added to the above mixture to block phage adsorption.
- the bacterial cells were spun down and resuspended in 500 ⁇ l of 20mM sodium citrate.
- Transductants were selected on TSB-agar containing 500 ⁇ g/ml of sodium citrate and 5 ⁇ g/ml of Erm, and transductants YJ335, YJ318-7, and YJ318-16 containing plasmids pYJ335, pYJ318-7, and pYJ318- 16, respectively, were confirmed by restriction enzyme digestion.
- the 621-bp hla fragment was generated by PCR using /j/ ⁇ -specific primers.
- the antisense hla and sense hla orientations in plasmids pYJ318-7 and pYJ318-16, respectively, were confirmed by PCR using the plasmid-specific primer ret/?Forl 399 (5' CAATACATTGTAGGCTGC 3 [SEQ ID NO:3] corresponding to nucleotides 1399-1416 and j/ ⁇ -specific primers z/ ⁇ Rev684 (reverse) and hlaFor64 (forward).
- the reaction conditions for all PCR's were 0.2mM dNTPs, 2.5mM MgCl2, 50 pmol of each primer, and 2.5 U of Taq polymerase in buffer supplied by the manufacturer (Gibco-BRL, Cockeysville, MD).
- the primers were tetRFor ⁇ 399 and hlaFor64, and tetRFor ⁇ 394 and /?/ ⁇ Rev684, respectively, using the same annealing temperature of 48° C.
- bacterial RNA was isolated from infected tissue samples using FastRNA reagents (BIO101 , Vista, CA) and treated with RNase-free DNasel (GeneHunter Corp., Nashville, TN ) to remove DNA. Single-stranded cDNA was synthesized by incubating Dnase-treated RNA with reverse transcriptase in reaction buffer supplied by the manufacturer (Gibco-BRL, Gaithersburg, MD).
- cDNA was used as the template for PCR using the tgtR-c ⁇ f-specific primers, tetRFor] 399 and c ⁇ tRev768 (5' GGCAGGTTAGTGACATTAG 3 ⁇ [SEQ ID NO:4], and the hla gene-specific primers, hlaFor64 and hlaRev684.
- DNA sequencing was performed to further confirm the tet regulatory elements in pYJ335, and the antisense hla and sense hla orientations in pYJ318-7 and pYJ318-16, respectively.
- CAT activity was determined spectrophotometrically as described by Shaw (W.V.
- the bacterial cells were harvested by centrifugation and washed once with 25mM Tris pH 7.8, lOmM EDTA (TE) buffer. Crude protein extracts were prepared by centrifugation after the bacterial cells had been suspended in 200 ⁇ l of TE buffer containing 0.2mg/ml of lysostaphin (Sigma, St. Louis, MO) and incubated at 37°C for 10 minutes. The total protein concentration was determined by using the Bio-Rad protein microassay (Bio-Rad Lab., Hercules, CA). Specific CAT activity was calculated as the number of units of CAT activity per mg total protein. Experiments were performed in triplicate at lease twice and similar results were obtained.
- Tc was added to 10-ml cultures of S. aureus WCUH29, YJ318-7 and YJ318-16 to a final concentration of 250ng/ml and incubated with shaking at 37°C for 8 hours. Supernatants were collected after centrifugation and transferred into tubes containing an equal volume of ethanol and incubated overnight at 4°C. Extracellular proteins were precipitated by centrifugation at 15,000 x g at 4°C for 30 minutes. SDS-PAGE and Western blotting methods used were performed as previously described (U.K. Laemmli, Nature, 1970, 227:680-685). Equal amounts of protein were loaded into each lane of a 12.5% SDS-PAGE gel. Standard ⁇ - hemolysin and anti-rabbit antibody alkaline phosphatase conjugate were from Sigma (St.
- Murine hematogenous pyelonephritis infection model Murine hematogenous pyelonephritis infection model.
- CD- 1 female mice obtained from Charles River Laboratories were used for in vivo assays.
- S. aureus YJ335 and YJ318-16 were harvested from 1 ml of stationary phase culture, washed once with 1 ml of PBS, and diluted to an A 00 of 0.2. These bacterial suspensions were diluted and plated onto TSB-agar plates for determination of viable CFU.
- Three mice per group were infected with about 10 ' CFU of bacteria via an intravenous injection of 0.2 ml of bacterial suspension into the tail vein using a tuberculin syringe. Different doses of Tc were given orally in 0.2ml doses to infected mice on days 1, 2, and 3 after infection.
- mice were sacrificed by carbon dioxide overdose 2 hours after the last dose of Tc induction. Kidneys were aseptically removed and each pair was cleaved in half; one half was snap-frozen in cryovials in liquid nitrogen, and the other half was homogenized in 1ml of PBS for enumeration of viable bacteria. The frozen samples were subsequently used for RT-PCR analysis.
- the Tn/0-encoded tet regulatory element was used as an inducible expression system in S. aureus.
- This system consists of the tetR gene, the tetR promoter, and the strong xyl/tet promoter-operator fusion to direct expression of the cat gene as a reporter to monitor the level of induction (Fig. 1).
- the tet regulatory elements and the cat gene were cloned into the E. coli-S. aureus shuttle vector pYJ90 as described elsewhere herein.
- the resulting plasmid, pYJ335, was found to be stably maintained in S. aureus following multiple passages in the absence of selection (data not shown).
- strain YJ335 was determined in vitro following induction with tetracycline.
- the effect of Tc on the expression of cat in strain YJ335 was measured 3 hours after incubation with different doses of Tc in log phase cultures. The results of this experiment are shown in Figure 2.
- strain YJ335 showed a basal level of cat activity and could not grow on TSB-agar plates containing Cm (l ⁇ g/ml). However, cat expression was induced efficiently when Tc was added to the culture medium.
- Example 14 Construction of isogenic strains producing sense and antisense hla transcripts in 5. aureus WCUH29.
- RNA In order to determine whether induced antisense RNA can down-regulate expression of chromosomal genes efficiently in S. aureus, a 621-bp fragment of the hla gene containing the promoter region was inserted into the Smal site downstream of the xyl/tet promoter-operator fusion in the shuttle vector pYJ335 (Fig. 4). The orientation of the hla insertion was ascertained by PCR using the plasmid-specific primer ter/?Forl399 and two M ⁇ -specific primers Z ⁇ / For64 and Z./ Rev684.
- Transformants were selected by Erm resistance and plasmids were confirmed using restriction enzyme digestion
- the resulting isogenic strains, YJSB 18-7 and YJSB318-16, were used to make phage lysates for transduction as described elswhere herein
- the resulting transductants were used to characterize hla antisense function in vitro and in vivo
- RNA from YJ318-7 and YJ318- 16 grown in the presence and absence of 250ng/ml Tc were electrophoresed on an agarose-formaldehyde gel, blotted onto a nylon membrane, and hybridized to different DIG-labeled single-stranded DNA oligonucleotide probes specific for antisense hla RNA and sense hla RNA (Fig 5)
- the blot showed that RNA from strain YJ318-7 after Tc induction contained an antisense hla RNA transcript that hybridized to the antisense DNA probe, in contrast, RNA from strain YJ318-7 without Tc induction did not show the antisense hla RNA transcript
- RNA prepared from YJ318-16 with Tc induction nor RNA from YJ318-16 without induction contained
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Environmental Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Immunology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000523383A JP2002503447A (en) | 1997-12-04 | 1998-12-04 | Method for obtaining conditionally expressed mutant cells using expressible antisense sequence |
EP98962914A EP1034308A4 (en) | 1997-12-04 | 1998-12-04 | Method of generating conditionally expressed mutant cells using expressible antisense sequences |
US11/017,379 US20050095643A1 (en) | 1997-12-04 | 2004-12-20 | Method of generating conditionally expressed mutant cells using expressible antisense sequences |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6744697P | 1997-12-04 | 1997-12-04 | |
US60/067,446 | 1997-12-04 | ||
US8253498P | 1998-04-20 | 1998-04-20 | |
US60/082,534 | 1998-04-20 | ||
US10516198P | 1998-10-21 | 1998-10-21 | |
US60/105,161 | 1998-10-21 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09581479 A-371-Of-International | 2000-05-25 | ||
US10/099,198 Continuation US20030124507A1 (en) | 1997-12-04 | 2002-03-13 | Method of generating conditionally expressed mutant cells using expressible antisense sequences |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999028508A1 true WO1999028508A1 (en) | 1999-06-10 |
Family
ID=27371157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/025808 WO1999028508A1 (en) | 1997-12-04 | 1998-12-04 | Method of generating conditionally expressed mutant cells using expressible antisense sequences |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1034308A4 (en) |
JP (1) | JP2002503447A (en) |
WO (1) | WO1999028508A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1047453A1 (en) * | 1998-01-21 | 2000-11-02 | Smithkline Beecham Corporation | Method for determining gene essentiality in a pathogen |
US6228579B1 (en) | 1997-11-14 | 2001-05-08 | San Diego State University Foundation | Method for identifying microbial proliferation genes |
WO2002051982A2 (en) * | 2000-12-27 | 2002-07-04 | Elitra Pharmaceuticals, Inc. | Bacterial promoters and methods of use |
WO2002083940A2 (en) * | 2001-04-06 | 2002-10-24 | Creatogen Aktiengesellschaft | Screening method for anti-microbial drug targets by genome-saturing mutagenesis (gsm) |
US6720139B1 (en) | 1999-01-27 | 2004-04-13 | Elitra Pharmaceuticals, Inc. | Genes identified as required for proliferation in Escherichia coli |
WO2004101757A2 (en) | 2003-05-07 | 2004-11-25 | E.I. Dupont De Nemours And Company | Production of polyunsaturated fatty acids in oleaginous yeasts |
WO2005047479A2 (en) | 2003-11-12 | 2005-05-26 | E.I. Dupont De Nemours And Company | Delta-15 desaturases suitable for altering levels of polyunsaturated fatty acids in oilseed plants and oleaginous yeast |
WO2006052870A2 (en) | 2004-11-04 | 2006-05-18 | E.I. Dupont De Nemours And Company | High eicosapentaenoic acid producing strains of yarrowia lipolytica |
WO2010080388A1 (en) | 2008-12-18 | 2010-07-15 | E. I. Du Pont De Nemours And Company | Reducing byproduction of malonates in a fermentation process |
WO2012134978A2 (en) | 2011-04-01 | 2012-10-04 | Ice House America, Llc | Ice bagging apparatus and methods |
CN105018528A (en) * | 2015-08-20 | 2015-11-04 | 重庆大学 | Multi-gene expression and silencing system controlled by heat shock protein gene promoter and tetracycline gene promoter |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5639595A (en) * | 1990-05-01 | 1997-06-17 | Isis Phamaceuticals, Inc. | Identification of novel drugs and reagents |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE361990T1 (en) * | 1996-11-13 | 2007-06-15 | Qbi Entpr Ltd | GENE IDENTIFICATION PROCEDURE |
JP2001524317A (en) * | 1997-11-21 | 2001-12-04 | エール・ユニバーシティ | Methods for identifying and inhibiting functional nucleic acid molecules in cells |
-
1998
- 1998-12-04 JP JP2000523383A patent/JP2002503447A/en not_active Withdrawn
- 1998-12-04 EP EP98962914A patent/EP1034308A4/en not_active Withdrawn
- 1998-12-04 WO PCT/US1998/025808 patent/WO1999028508A1/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5639595A (en) * | 1990-05-01 | 1997-06-17 | Isis Phamaceuticals, Inc. | Identification of novel drugs and reagents |
Non-Patent Citations (1)
Title |
---|
See also references of EP1034308A4 * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6924101B2 (en) | 1997-11-14 | 2005-08-02 | San Diego State University Foundation | Methods for identifying anti-microbial agents |
US6228579B1 (en) | 1997-11-14 | 2001-05-08 | San Diego State University Foundation | Method for identifying microbial proliferation genes |
EP1047453A4 (en) * | 1998-01-21 | 2002-08-28 | Smithkline Beecham Corp | Method for determining gene essentiality in a pathogen |
EP1047453A1 (en) * | 1998-01-21 | 2000-11-02 | Smithkline Beecham Corporation | Method for determining gene essentiality in a pathogen |
US6720139B1 (en) | 1999-01-27 | 2004-04-13 | Elitra Pharmaceuticals, Inc. | Genes identified as required for proliferation in Escherichia coli |
WO2002051982A2 (en) * | 2000-12-27 | 2002-07-04 | Elitra Pharmaceuticals, Inc. | Bacterial promoters and methods of use |
WO2002051982A3 (en) * | 2000-12-27 | 2009-08-06 | Elitra Pharmaceuticals Inc | Bacterial promoters and methods of use |
WO2002083940A3 (en) * | 2001-04-06 | 2004-02-19 | Creatogen Ag | Screening method for anti-microbial drug targets by genome-saturing mutagenesis (gsm) |
US7390620B2 (en) | 2001-04-06 | 2008-06-24 | Creatogen Laboratories Gmbh | Screening method for anti-microbial drug targets by genome-saturating mutagenesis (GSM) |
WO2002083940A2 (en) * | 2001-04-06 | 2002-10-24 | Creatogen Aktiengesellschaft | Screening method for anti-microbial drug targets by genome-saturing mutagenesis (gsm) |
EP2392664A2 (en) | 2003-05-07 | 2011-12-07 | E. I. du Pont de Nemours and Company | Production of polyunsaturated fatty acids in oleaginous yeasts |
WO2004101757A2 (en) | 2003-05-07 | 2004-11-25 | E.I. Dupont De Nemours And Company | Production of polyunsaturated fatty acids in oleaginous yeasts |
EP2402448A2 (en) | 2003-05-07 | 2012-01-04 | E. I. du Pont de Nemours and Company | Production of polyunsaturated fatty acids in oleaginous yeasts |
EP2392665A2 (en) | 2003-05-07 | 2011-12-07 | E. I. du Pont de Nemours and Company | Production of polyunsaturated fatty acids in oleaginous yeasts |
WO2005047480A2 (en) | 2003-11-12 | 2005-05-26 | E.I. Dupont De Nemours And Company | Delta-15 desaturases suitable for altering levels of polyunsaturated fatty acids in oleaginous plants and yeast |
WO2005047479A2 (en) | 2003-11-12 | 2005-05-26 | E.I. Dupont De Nemours And Company | Delta-15 desaturases suitable for altering levels of polyunsaturated fatty acids in oilseed plants and oleaginous yeast |
WO2006052870A2 (en) | 2004-11-04 | 2006-05-18 | E.I. Dupont De Nemours And Company | High eicosapentaenoic acid producing strains of yarrowia lipolytica |
EP2458000A1 (en) | 2004-11-04 | 2012-05-30 | E. I. du Pont de Nemours and Company | High arachidonic acid producing strains of yarrowia lipolytica |
EP2649887A2 (en) | 2004-11-04 | 2013-10-16 | E. I. du Pont de Nemours and Company | High eicosapentaenoic acid producing strains of Yarrowia lipolytica |
WO2010080388A1 (en) | 2008-12-18 | 2010-07-15 | E. I. Du Pont De Nemours And Company | Reducing byproduction of malonates in a fermentation process |
WO2012134978A2 (en) | 2011-04-01 | 2012-10-04 | Ice House America, Llc | Ice bagging apparatus and methods |
CN105018528A (en) * | 2015-08-20 | 2015-11-04 | 重庆大学 | Multi-gene expression and silencing system controlled by heat shock protein gene promoter and tetracycline gene promoter |
Also Published As
Publication number | Publication date |
---|---|
EP1034308A4 (en) | 2002-04-03 |
EP1034308A1 (en) | 2000-09-13 |
JP2002503447A (en) | 2002-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zighelboim et al. | Penicillin-binding proteins of multiply antibiotic-resistant South African strains of Streptococcus pneumoniae | |
Dunny et al. | Transmissible toxin (hemolysin) plasmid in Streptococcus faecalis and its mobilization of a noninfectious drug resistance plasmid | |
Li et al. | Cell density modulates acid adaptation in Streptococcus mutans: implications for survival in biofilms | |
US5434065A (en) | In vivo selection of microbial virulence genes | |
KR20170121291A (en) | Engineered bacteria to treat diseases that benefit from reduced intestinal inflammation and / or enhanced intestinal mucosal barriers | |
US20200109395A1 (en) | Genetic systems that defend against foreign dna and uses thereof | |
Li et al. | Myxococcus xanthus viability depends on groEL supplied by either of two genes, but the paralogs have different functions during heat shock, predation, and development | |
US6436694B1 (en) | Regulable gene expression in gram-positive bacteria | |
EP1034308A1 (en) | Method of generating conditionally expressed mutant cells using expressible antisense sequences | |
Jackson et al. | A widely conserved bacterial cytoskeletal component influences unique helical shape and motility of the spirochete Leptospira biflexa | |
CA2223519A1 (en) | Methods for evaluation of antimicrobial targets | |
US7056728B2 (en) | Compositions and methods for use thereof in modifying the genomes of microorganisms | |
US20230022575A1 (en) | Bacterial conjugative system and therapeutic uses thereof | |
JP2010539965A (en) | Transcription factor decoy, compositions and methods | |
US20050095643A1 (en) | Method of generating conditionally expressed mutant cells using expressible antisense sequences | |
US20050032093A1 (en) | Novel genes involved in the escherichia coli biofilm formation and uses thereof | |
JPH10191990A (en) | Method for determing gene essentiality in a pathogen | |
Ma et al. | Point mutations in a peptidoglycan biosynthesis gene cause competence induction in Haemophilus influenzae | |
Coque | Evolutionary biology of pathogenic enterococci | |
JP2021524230A (en) | Systems and methods for genetic engineering of Akkermansia species | |
Cvitkovitch et al. | Tn 917 transposon mutagenesis and marker rescue of interrupted genes of Streptococcus mutans | |
US6309817B1 (en) | Identification of virulence determinants activators in prokaryotic pathogens | |
Blinkowa et al. | Physiological properties of cold-sensitive suppressor mutations of a temperature-sensitive dnaZ mutant of Escherichia coli | |
US7390620B2 (en) | Screening method for anti-microbial drug targets by genome-saturating mutagenesis (GSM) | |
WO2002008431A1 (en) | Compositions and methods for use thereof in modifying the genomes of microorganisms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998962914 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09581479 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 523383 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1998962914 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998962914 Country of ref document: EP |